Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (32)

2024

  1. Analysis of myocardial infarction incidence and case-fatality in the last three decades in the province of Girona

    Revista Espanola de Cardiologia, Vol. 77, Núm. 6, pp. 450-458

  2. Association between N-terminal pro-brain natriuretic peptide and maximal functional capacity in heart failure with preserved ejection fraction: The modifying role of obesity

    Obesity Research and Clinical Practice

  3. Carbohydrate antigen 125-guided pre-TAVI medical optimization: impact on quality of life and clinical outcomes

    Revista Espanola de Cardiologia

  4. Catheter-directed therapy for acute pulmonary embolism: results of a multicenter national registry

    Revista Espanola de Cardiologia, Vol. 77, Núm. 2, pp. 138-147

  5. ChatGPT-4 versus human assessment in cardiology peer review

    Revista Espanola de Cardiologia

  6. Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: A secondary analysis of the myPACE trial

    European Journal of Heart Failure, Vol. 26, Núm. 1, pp. 167-176

  7. Impact of Epicardial Adipose Tissue on Infarct Size and Left Ventricular Systolic Function in Patients with Anterior ST-Segment Elevation Myocardial Infarction

    Diagnostics, Vol. 14, Núm. 4

  8. Noncardiovascular morbidity and mortality across left ventricular ejection fraction categories following hospitalization for heart failure

    Revista Espanola de Cardiologia, Vol. 77, Núm. 3, pp. 206-214

  9. Short-Course High-Intensity Statin Treatment during Admission for Myocardial Infarction and LDL-Cholesterol Reduction—Impact on Tailored Lipid-Lowering Therapy at Discharge

    Journal of Clinical Medicine, Vol. 13, Núm. 1

  10. Urinary Cell Cycle Arrest Biomarkers and Diuretic Efficiency in Acute Heart Failure

    CardioRenal Medicine, Vol. 14, Núm. 1, pp. 261-269

  11. β-Blocker Withdrawal and Functional Capacity Improvement in Patients with Heart Failure with Preserved Ejection Fraction

    JAMA Cardiology, Vol. 9, Núm. 4, pp. 392-396

2023

  1. An update on utilising brain natriuretic peptide for risk stratification, monitoring and guiding therapy in heart failure

    Expert Review of Molecular Diagnostics, Vol. 23, Núm. 6, pp. 521-533

  2. Changes in the Treatment Strategy Following Intracoronary Pressure Wire in a Contemporaneous Real-Life Cohort of Patients With Intermediate Coronary Stenosis. Results From a Nationwide Registry

    Cardiovascular Revascularization Medicine, Vol. 51, pp. 55-64

  3. Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 511-518

  4. Clinical Predictors and Prognosis of Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) without ST-Segment Elevation in Older Adults

    Journal of Clinical Medicine, Vol. 12, Núm. 3

  5. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  6. Long-term outcomes of extended DAPT in a real-life cohort of consecutive STEMI patients

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 548-554

  7. Performance of an artificial intelligence chatbot with web search capability in cardiology-related assistance: a simulation study

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1065-1067

  8. Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome

    ESC Heart Failure, Vol. 10, Núm. 1, pp. 264-273

  9. Role of plasma carbohydrate antigen 125 to identify nonfrail patients in HF

    REC: CardioClinics, Vol. 58, Núm. 3, pp. 172-179